Linezolid for the treatment of community- acquired pneumonia in hospitalized children

Objective. To determine the safety, tolerance, pharmacokinetics and efficacy of linezolid, a new oxazolidinone antibiotic in the treatment of community-acquired pneumonia in hospitalized children. Design. A Phase II, open label multicenter study of intravenous linezolid followed by oral linezolid suspension, both at a dose of 10 mg/kg every 12 h. Efficacy was assessed at 7 to 14 days after the last dose of linezolid. Patients. Children 12 months to 17 years old with community-acquired pneumonia admitted to the hospital of 14 participating centers. Results. From July 21, 1998, through May 14, 1999, 79 children were enrolled and 78 received linezolid. Sixty-six children completed treatment and follow-up and were evaluable for clinical outcome. The median age of the evaluable patients was 3 years (range, 1 to 12 years); 47 were 2 to 6 years old. Pathogens were isolated from blood or pleural fluid cultures in 8 children:Streptococcus pneumoniae, 6 (2 penicillin-resistant); Group A Streptococcus, 1; methicillin-resistant Staphylococcus aureus, 1. Chest tubes were placed in 9 patients. The mean total duration of intravenous and oral administration was 12.2 ± 6.2 days (range, 6 to 41 days). The mean peak and trough plasma concentrations of linezolid were 9.5 ± 4.8 and 0.8 ± 1.2 &mgr;g/ml, respectively. At the follow-up visit 7 to 14 days after the last dose of linezolid, 61 patients (92.4%) were considered cured including all the patients with proven pneumococcal pneumonia, one failed (methicillin-resistant Staphylococcus aureus) and 4 were considered indeterminate. The most common adverse effects in the intent to treat group were diarrhea (10.3%), neutropenia (6.4%) and elevation in alanine aminotransferase (6.4%). Conclusions. Linezolid was well-tolerated and could be considered an alternative to vancomycin for treating serious infections caused by antibiotic-resistant Gram-positive cocci in children pending results of additional studies.

[1]  G. Kearns,et al.  Single dose pharmacokinetics of linezolid in infants and children , 2000, The Pediatric infectious disease journal.

[2]  A. Schuchat,et al.  Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. , 2000, American journal of public health.

[3]  S. Wilson,et al.  Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group. , 1999, The Journal of antimicrobial chemotherapy.

[4]  M. Leinonen,et al.  Etiology and treatment of community-acquired pneumonia in ambulatory children. , 1999, The Pediatric infectious disease journal.

[5]  R. Moellering.  A Novel Antimicrobial Agent Joins the Battle against Resistant Bacteria , 1999, Annals of Internal Medicine.

[6]  H. Aoki,et al.  The Oxazolidinone Linezolid Inhibits Initiation of Protein Synthesis in Bacteria , 1998, Antimicrobial Agents and Chemotherapy.

[7]  M. Pfaller,et al.  Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  Sheldon L. Kaplan,et al.  Management of Infections Due to Antibiotic-Resistant Streptococcus pneumoniae , 1998, Clinical Microbiology Reviews.

[9]  C. Deangelis.  Principles and Practice of Pediatric Infectious Diseases , 1998 .

[10]  J. Bartlett,et al.  Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  D. Lauderdale,et al.  Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. , 1998, JAMA.

[12]  P. Daley-Yates,et al.  Serum inhibitory titers and serum bactericidal titers for human subjects receiving multiple doses of the antibacterial oxazolidinones eperezolid and linezolid. , 1997, Diagnostic microbiology and infectious disease.

[13]  J. Kilburn,et al.  In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents , 1996, Antimicrobial agents and chemotherapy.

[14]  S. Kaplan,et al.  In vitro activities of oxazolidinones U-100592 and U-100766 against penicillin-resistant and cephalosporin-resistant strains of Streptococcus pneumoniae , 1996, Antimicrobial agents and chemotherapy.

[15]  R. Jones,et al.  In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones , 1996, Antimicrobial agents and chemotherapy.

[16]  A. Pisciotta.  Agranulocytosis during antibiotic therapy: Drug sensitivity or sepsis? , 1993, American journal of hematology.

[17]  L. Frenkel.  Once-daily administration of ceftriaxone for the treatment of selected serious bacterial infections in children. , 1988, Pediatrics.

[18]  J. Nelson,et al.  Cefuroxime therapy for pneumonia in infants and children. , 1982, Pediatric infectious disease.

[19]  F. Oski.  Hematologic consequences of chloramphenicol therapy. , 1979, The Journal of pediatrics.

[20]  J. McCullers,et al.  Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae from the cerebrospinal fluid of a patient who developed recrudescent meningitis. , 2000, The Journal of infectious diseases.

[21]  Paterick Bd,et al.  Geographic variation in penicillin resistance in Streptococcus pneumoniae--selected sites, United States, 1997. , 1999, MMWR. Morbidity and mortality weekly report.

[22]  S. Cosgrove,et al.  Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997. , 1997, MMWR. Morbidity and mortality weekly report.

[23]  J. Wouters,et al.  Experimental and theoretical study of reversible monoamine oxidase inhibitors: structural approach of the active site of the enzyme. , 1994, Journal of neural transmission. Supplementum.

[24]  M. Finland,et al.  Resistance of Staphylococcus aureus to lincomycin, clinimycin, and erythromycin. , 1968, Antimicrobial agents and chemotherapy.

[25]  C. Cabellos,et al.  Anti b iotic res istant Streptococcus pneumoniae , 2022 .